Coherus Oncology, Inc. (NASDAQ: CHRS)

Coherus BioSciences, Inc. (CHRS) is a commercial-stage biopharmaceutical company operating in the healthcare industry. The company is primarily involved in the research, development, and commercialization of innovative cancer treatments and the commercialization of its portfolio of FDA-approved oncology products. Coherus BioSciences has a significant presence in the oncology and biosimilar segments, with a focus on developing novel PD-1 inhibitors and biosimilar products.

The company's main business activities are centered around its immuno-oncology franchise, which includes the development of novel PD-1 inhibitors, as well as its biosimilar products, including UDENYCA, YUSIMRY, and CIMERLI. Coherus BioSciences' immuno-oncology franchise is a significant area of focus for the company, as it has the potential to become a leading franchise in the immuno-oncology space. The company's biosimilar products are also a crucial part of its business, as they provide a competitive advantage in the market.

Coherus BioSciences generates revenue primarily through the sale of its commercial products, including UDENYCA, YUSIMRY, and CIMERLI, as well as through the development and commercialization of its pipeline products, including LOQTORZI, casdozokitug, CHS-114, and CHS-1000. UDENYCA is a biosimilar to Neulasta, a long-acting G-CSF, and is approved by the FDA for the treatment of neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. YUSIMRY is a biosimilar to Humira, a tumor necrosis factor (TNF) inhibitor, and is approved by the FDA for the treatment of various inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. CIMERLI is a biosimilar to Lucentis, a vascular endothelial growth factor (VEGF) inhibitor, and is approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

In the Oncology segment, Coherus BioSciences is focused on the development and commercialization of innovative cancer treatments, including LOQTORZI, a novel PD-1 inhibitor. LOQTORZI is approved by the FDA for the treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The company launched LOQTORZI in the United States in January 2024 and has established a commercial team to support the product's launch and growth.

Coherus BioSciences has a number of competitive advantages, including its biologics platform, knowledge, experience, and scientific resources. The company's biologics platform allows it to develop and commercialize innovative cancer treatments, including LOQTORZI, which has the potential to become a leading PD-1 inhibitor in the market. The company's knowledge and experience in the development and commercialization of biosimilar products, including UDENYCA, YUSIMRY, and CIMERLI, also provide it with a competitive advantage in the market.

The company's customers include healthcare providers, hospitals, and patients. Coherus BioSciences' products are used to treat a range of diseases, including cancer, inflammatory diseases, and eye diseases. The company's marketing and sales efforts are focused on promoting its products to healthcare providers, hospitals, and patients. The company has established a commercial team to support the launch and growth of its products, including LOQTORZI, UDENYCA, YUSIMRY, and CIMERLI.